Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Benz

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
American Heart Journal|June 1, 2020
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillationGanesan Karthikeyan, Stuart J Connolly, Mpiko Ntsekhe, et al.
The New England Journal of Medicine|August 29, 2022
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial FibrillationStuart J Connolly, Ganesan Karthikeyan, Mpiko Ntsekhe, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
American Heart Journal|June 1, 2020
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillationGanesan Karthikeyan, Stuart J Connolly, Mpiko Ntsekhe, et al.
The New England Journal of Medicine|August 29, 2022
Rivaroxaban in Rheumatic Heart Disease-Associated Atrial FibrillationStuart J Connolly, Ganesan Karthikeyan, Mpiko Ntsekhe, et al.
Pageof 3